Novartis的PluvictoTM在早期前列腺癌中显示出前景,在临床试验中延长了存活期。 Novartis's Pluvicto™ shows promise in early prostate cancer, extending survival in clinical trial.

Novartis的PluvictoTM显示,在第三阶段的试验中,对转移性荷尔蒙敏感的前列腺癌患者有很大好处,在与标准的荷尔蒙治疗相结合的情况下,延长了无放射分程存活期。 Novartis's Pluvicto™ showed significant benefits in a Phase III trial for patients with metastatic hormone-sensitive prostate cancer, extending radiographic progression-free survival when combined with standard hormone therapy. 该试验达到其主要终点,在总体存活方面呈现出积极趋势,表明PluvictoTM在疾病的早期阶段可能有效。 The trial met its primary endpoint and showed a positive trend in overall survival, suggesting Pluvicto™ could be effective in earlier stages of the disease. Novartis计划在今年晚些时候在一次医疗会议上提交调查结果,并寻求监管批准。 Novartis plans to present the findings at a medical conference and seek regulatory approval later this year.